Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb Study of EHSG-KF vs Split-Thickness Skin Grafts in Burns
2024-512188-29-00Phase 2Completed
- Sponsor
- CUTISS
- Start
- Oct 2024
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of denovoSkin in burn injury and Skin and connective tissue disease (2 arms), sponsored by CUTISS. Primary endpoint: Primary efficacy endpoint: ratio of covered surface area to biopsy/donor site surface area at 28 ± 3 days post grafting. Started Oct 2024; status: completed.
02
Drugs
denovoSkin
03
Conditions
burn injurySkin and connective tissue disease
Beyond the preview
Go deeper on 2024-512188-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512188-29-00.